IL-37通过将巨噬细胞塑造为非炎性吞噬表型来阻断痛风性炎症
本研究探讨IL-37是否通过改变巨噬细胞功能抑制痛风性炎症及其机制。IL-37促进巨噬细胞对MSU的吞噬、减少焦亡相关蛋白转录和炎性细胞因子释放、保护线粒体功能并介导代谢重编程,部分依赖GSK-3β。IL-37可能成为慢性痛风尤其痛风石患者的潜在治疗选择。
要点
- IL-37促进巨噬细胞吞噬MSU并减少焦亡相关蛋白转录和炎性细胞因子释放。
- IL-37保护线粒体功能并介导代谢重编程,部分依赖GSK-3β。
- IL-37可能成为慢性痛风尤其痛风石患者的潜在治疗选择。
核心结论
- IL-37可将巨噬细胞塑造为「沉默」的非炎性吞噬表型。
- IL-37可能成为慢性痛风尤其痛风石患者的潜在治疗选择。
研究设计与样本
- 在MSU处理的THP-1细胞中评估巨噬细胞吞噬、焦亡、极化和代谢功能。
- 通过CRISPR/Cas介导的基因组工程创建人IL-37敲入小鼠及小鼠Gsk3b位点S9A点突变模型。
- 向小鼠爪和腹腔注射MSU建立急性痛风模型,用游标卡尺测量爪厚度。
- 收集小鼠爪、人滑膜组织或痛风石进行病理染色,用小鼠腹腔液富集巨噬细胞检测极化。
主要发现
- IL-37增强MSU处理的THP-1细胞对MSU的吞噬。
- IL-37减少MSU处理的THP-1细胞焦亡相关蛋白转录和炎性细胞因子释放。
- IL-37保护MSU处理的THP-1细胞线粒体功能并介导代谢重编程。
- IL-37的这些多重作用部分依赖糖原合成酶激酶-3β(GSK-3β)的介导。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Interleukin (IL)-37 is a natural suppressor of inflammation. Macrophages play an important role in acute gout flare by dominating the inflammation and spontaneous relief. We have reported that IL-37 could limit runaway inflammation in gout. Here we focus on whether IL-37 inhibits gouty inflammation by altering macrophage functions, and how it does so. METHODS: Macrophage functions were evaluated in terms of phagocytosis, pyroptosis, polarization and metabolism. Phagocytosis and polarization of macrophages were detected by side scattering and double-labelling induced nitrogen monoxide synthase (iNOS)/arginase-1 (Arg-1) using flow cytometry, respectively. Transcription of pyroptosis-related molecules was detected by qPCR. Metabolomics was performed by liquid chromatograph mass spectrometer. Human IL-37 knock-in mice and a model with point mutation (S9A) at mouse Gsk3b locus were created by CRISPR/Cas-mediated genome engineering. MSU was injected into the paws and peritoneal cavity to model acute gout. Vernier calliper was used to measure the thickness of the paws. The mice paws and human synovium tissues or tophi were collected for pathological staining. Peritoneal fluid of mice was used to enrich macrophages to detect polarization. RESULTS: IL-37 promoted non-inflammatory phagocytic activity of macrophages by enhancing phagocytosis of MSU, reducing transcription of pyroptosis-related proteins and release of inflammatory cytokines, protecting mitochondrial function, and mediating metabolic reprogramming in MSU-treated THP-1 cells. These multifaceted roles of IL-37 were partly depended on the mediation of glycogen synthase kinase-3β (GSK-3β). CONCLUSIONS: Our study revealed that IL-37 could shape macrophages into a 'silent' non-inflammatory phagocytic fashion. IL-37 may become a potentially valuable treatment option for patients of chronic gout, especially for those with tophi.
引用
- Zhao L, Zhao T, Yang X, et al. IL-37 blocks gouty inflammation by shaping macrophages into a non-inflammatory phagocytic phenotype. Rheumatology (Oxford). 2022. PMID: 35015844. doi:10.1093/rheumatology/keac009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。